Sysmex (OTCMKTS:SSMXY) Hits New 52-Week High – Still a Buy?

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s share price reached a new 52-week high during trading on Thursday. The company traded as high as $13.01 and last traded at $12.41, with a volume of 1,624 shares traded. The stock had previously closed at $11.82.

Analysts Set New Price Targets

Separately, Zacks Research raised Sysmex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 18th. Two investment analysts have rated the stock with a Hold rating. According to MarketBeat, the stock currently has a consensus rating of “Hold”.

Sysmex Stock Up 0.3%

The firm has a market cap of $7.56 billion, a P/E ratio of 29.60 and a beta of 1.18. The firm’s fifty day moving average is $11.90 and its 200 day moving average is $10.14. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.53 and a current ratio of 3.40.

Sysmex (OTCMKTS:SSMXY) last released its quarterly earnings results on Friday, August 7th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.02. The firm had revenue of $825.85 million for the quarter, compared to analysts’ expectations of $741.67 million. Sysmex had a net margin of 7.62% and a return on equity of 8.01%. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. As a group, equities research analysts anticipate that Sysmex Corporation ADR will post 0.41 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation is a Japan-based healthcare technology company that develops, manufactures and distributes clinical laboratory instruments, reagents and related information systems. Its products are used by hospitals, diagnostic laboratories and other healthcare providers to support the analysis of blood, urine and other biological samples.

The company is best known for its hematology analyzers, which help laboratories evaluate blood cells and identify conditions such as anemia and leukemia.